TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00949325
Drug: temsirolimus plus liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with temsirolimus (Torisel) weekly by IV and with liposomal doxorubicin (Doxil) (standard dose) by IV once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until dose limiting toxicity (DLT) occurred and the maximally tolerated dose (MTD) was identified. The MTD dose was the standard dose of temsirolimus used for the remainder of the study. Dose modifications were based on protocol parameters for toxicities.
Study: NCT02515318
Drug: Medical standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard medical treatment consists on:~Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).~Glucocorticoids:~Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.~- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β-lactamase inhibitor and fluoroquinolones.
Study: NCT02891226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01737892
Drug: Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
Study: NCT01737892
Drug: Arm C-Epinephrine Inhalation Aerosol CFC
Normalized name: epinephrine Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
Study: NCT00896532
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg administered intravenously
Study: NCT02363075
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
Study: NCT01634152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations once daily in the evening
Study: NCT03093714
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for FDL169
Study: NCT01349114
Drug: Placebo/sugar pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill/placebo
Study: NCT01152437
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
Study: NCT01480778
Drug: LNG+EE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
Study: NCT00237042
Drug: 20 mcg ethinyl estradiol and 100 mcg levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
Study: NCT00278109
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: chemotherapy
Study: NCT01468480
Drug: Pro Root MTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of MTA in second group and 24 hour interval before restoration
Study: NCT01468480
Drug: Pro Root MTA- single visit
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of MTA in third group and 15 minute interval before restoration
Study: NCT01468480
Drug: MultiCal
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of Multical in forth group as a pulp dressing agent
Study: NCT01468480
Drug: Dycal
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of Dycal in first group as a pulp dressing agent
Study: NCT00278109
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin
Study: NCT00720057
Drug: Naproxen Sodium ER (BAYH6689)
Normalized name: naproxen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
Study: NCT00720057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
Study: NCT02208856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01314833
Drug: Docetaxel Cyclophosphamide
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~TC\*6
Study: NCT01314833
Drug: Cyclophosphamide Fluorouracil Epirubicin Docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1~1 cycle = 21 days~4th-6th Cycle: Docetaxel 100mg/m² D1~1 cycle = 21 days CEF\*3-T\*3
Study: NCT01314833
Drug: Epirubicin Cyclophosphamide Paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1st-4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1~1 cycle = 21 days~5th-8th Cycle: Paclitaxel 80mg/m² D1, 8, 15~1 cycle = 21 days EC\*4-P\*4
Study: NCT02409459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution
Study: NCT01317745
Drug: MF59 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant/diluent manufactured by Novartis
Study: NCT02232542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00613015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00530881
Drug: PHX1149
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03659578
Drug: thymosin alpha 1
Normalized name: Thymosin alpha 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.
Study: NCT01145950
Drug: LBEC0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25mg, single dose
Study: NCT02332928
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
Study: NCT02332928
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
Study: NCT01265485
Drug: coated suppository
Normalized name: Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalating study
Study: NCT04464239
Drug: TS-142
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-142 tablets
Study: NCT04464239
Drug: TS-142 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-142 matching placebo tablets
Study: NCT00372957
Drug: GW823093 15mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: White opaque capsule containing 15mg of GW823093 as free base
Study: NCT00372957
Drug: GW823093 placebo capsule
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo of GW823093 capsule or 15mg capsule
Study: NCT00372957
Drug: GW823093 30mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: White opaque capsule containing 15mg of GW823093 as free base
Study: NCT00586794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3x per day, 20 mg TID
Study: NCT01889992
Drug: M-TOR Immunosuppression
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).~Sirolimus dosage based on blood levels.
Study: NCT02229136
Drug: Miracle Mouthwash Plus Hydrocortisone
Normalized name: hydrocortisone Rectal Cream [Recort Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
Study: NCT02229136
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone oral solution 15 mg/5 ml
Study: NCT03031808
Drug: Muscle Relaxant (Rocuronium)
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
Study: NCT04256525
Drug: low molecule heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4ml per day subcutaneous injection
Study: NCT00537043
Drug: SK&F-105517 (COREG CR FDC)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01069913
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequence 1: Oral 240 mg BG00012 Standard Formulation \& Following 7 day washout period, 240 mg BG00012 API.~Sequence 2: 240 mg BG00012 API \& Following 7 day washout period, 240 mg BG00012 Standard Formulation.
Study: NCT01110057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match GW856553
Study: NCT01110057
Drug: GS856553
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW586553 7.5mg bid
Study: NCT04115462
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching tablet of placebo
Study: NCT04115462
Drug: Cowhage (Mucuna Pruriens)
Normalized name: cowhage (Mucuna pruriens)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 spicules will be inserted in the centre of the predefined skin area on the forearm. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study: NCT04115462
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: A droplet of saline (0.9%) as vehicle control will be placed on the predetermined area on the forearm and the lancet will be pierced through the droplet.
Study: NCT04115462
Drug: Cowhage (Mucuna Pruriens)
Normalized name: cowhage (Mucuna pruriens)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 spicules will be inserted in the centre of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration
Study: NCT04622046
Drug: ALXN2060
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
Study: NCT00615576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
Study: NCT02665325
Drug: TSH-suppressive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
Study: NCT00844506
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
Study: NCT02087527
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV normal saline every 6 hours for 48 hours
Study: NCT01959165
Drug: MEDI7183 medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
Study: NCT01959165
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by SC on Day 1, Week 2,4, and 8
Study: NCT01128569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Inhaler
Study: NCT00894387
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02300233
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volanesorsen-matching placebo administered subcutaneously once-weekly for 26 weeks.
Study: NCT04435314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo TID for 7 days.
Study: NCT03745950
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Placebo will be administrated by oral at dose of 300 mg twice daily during the induction period and in maintenance
Study: NCT02746302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02115321
Drug: MK-5172A
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
Study: NCT01072526
Drug: Euphrasia-based homeopathic therapy
Normalized name: Euphrasia officinalis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution; 1 drop both eyes twice daily
Study: NCT01816295
Drug: Testosterone Solution
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered topically to axillae.
Study: NCT01816295
Drug: Placebo Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered topically to axillae.
Study: NCT03099122
Drug: Mycophenolate Na
Normalized name: MYCOPHENOLATE NA 180MG TAB,EC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule~Route of administration: oral
Study: NCT02448199
Drug: Meloxicam and Glucosamine
Normalized name: bupivacaine and meloxicam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT02448199
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT02448199
Drug: Glucosamine
Normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT03364153
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Injection
Study: NCT03792308
Drug: SPR206
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD Cohorts: Double-blind dosing will occur in Cohorts 1 - 8. Six participants will receive single doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur in Cohorts 9 - 13. Six participants in each cohort will receive multiple doses of SPR206. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 7 consecutive days for Cohorts 9 - 12 and for a total of 14 consecutive days for Cohort 13.
Study: NCT03792308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride for injection. SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Study: NCT04378868
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics are given while waiting surgery.
Study: NCT03400423
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1.2mg/kg of powdered caffeine with water.
Study: NCT02347605
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00329043
Drug: LHRH Agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection either monthly for 3 months or in a single 3-month dose.
Study: NCT03179878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03261830
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For use in Pre-operative Antibiotics arm in cases of documented allergy to primary intervention.
Study: NCT00897026
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00897026
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01991860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo given by single intravenous (IV) administration, by slow push over one minute, at induction of anaesthesia
Study: NCT04211363
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream for topical application.
Study: NCT02801786
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The arm will be composed of 03 women who used placebo capsules and gel.
Study: NCT02213029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: White to off white oral placebo tablets to match 5mg epelsiban
Study: NCT02213029
Drug: Ortho-Cylcen (21)® tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson \& Johnson
Study: NCT00658268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml, single dose mixed in bone graft at operation
Study: NCT00226005
Drug: PTK787/ZK222584
Approvals — FDA: no, EMA: no, PMDA: no
Description: One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
Study: NCT00967616
Drug: CS7017
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered by mouth (PO) BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
Study: NCT03675802
Drug: dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: giving dinoprostine
Study: NCT00967616
Drug: irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI will be administered IV once every 2 weeks.~The FOLFIRI regimen consists of:~* Irinotecan, 180 mg/m\^2 IV infusion over 30 to 120 minutes~* Leucovorin, 400 mg/m\^2 IV infusion to match the duration of the irinotecan infusion~* 5-FU, 1200 mg/m\^2/day x 2 days (total 2400 mg/m\^2 over 46 to 48 hours continuous infusion)
Study: NCT03627052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered orally twice daily in the double-blind period.
Study: NCT01215851
Drug: TMC207
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
Study: NCT01215851
Drug: Rifafour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifafour e-275
Study: NCT02951780
Drug: LY3185643
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT06098326
Drug: cyclophosphamide, fludarabine, and antithymocyte globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Cyclophosphamide 50 mg/kg/day i.v. daily on days -3 and -2 (for 2 days)~2. Fludarabine 30 mg/m2/day i.v. daily on days -7to -2 (for 6 days)~3. Antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day (for HLA-matched sibling donor HCT) or 3.0 mg/kg/day (for other alternative donor HCT) i.v. daily on days -3 to -1 (for 3 days)
Study: NCT03576235
Drug: PG102P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of 1.5g
Study: NCT03576235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of placebo
Study: NCT00790673
Drug: CF 102
Normalized name: californium Cf-249
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT00790673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT04561856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline 2ml
Study: NCT03700177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: modified pectoralis block for breast surgery with ropivacaine combined with placebo (NaCl 0,9%).
Study: NCT04349683
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 capsules at a time, 3 times a day (tid).
Study: NCT02669589
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01302925
Drug: PEP005 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP005 Gel 0.05% for 2 consecutive days
Study: NCT01302925
Drug: PEP005 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEP005 Gel 0.015% for 3 consecutive days
Study: NCT02297412
Drug: Minocycline Hydrochloride
Normalized name: Minocycline Hydrochloride
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04826198
Drug: AsiDNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unit dose: Vial containing 100 mg of AsiDNA™ (free acid) Regimen: 3 consecutive infusions (D1, D2, D3) followed by a once a week iv infusion on D8 and D15 of a 21 day-treatment cycle at first cycle, then weekly iv infusion in the absence of disease progression or unacceptable toxicity Mode/route: 1 hour intravenous (iv) infusion
Study: NCT02136784
Drug: hydrocodone
Normalized name: Hydrocodone
DrugBank: Hydrocodone (DB00956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study: NCT02136784
Drug: oral tablet placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
Study: NCT02136784
Drug: sublingual tablet placebo
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.